Open AccessGadolinium periconceptional exposure: pregnancy and neonatal outcome
Author(s) -
DE SANTIS M.,
STRAFACE G.,
CAVALIERE A.F.,
CARDUCCI B.,
CARUSO A.
Publication year - 2007
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1080/00016340600804639
Subject(s) - medicine , pregnancy , prospective cohort study , gadolinium , obstetrics , gestation , risk factor , magnetic resonance imaging , cohort study , teratology , fetus , radiology , genetics , materials science , metallurgy , biology
Background. Gadolinium derivatives are ionic paramagnetic contrast agents used to enhance magnetic resonance images, labeled as a pregnancy category C by the Food and Drug Administration because of a lack of epidemiological studies concerning first‐trimester exposure. Methods. Prospective cohort study to determine whether gadolinium derivatives exposure in periconceptional period is a risk factor for pregnancy or fetal development. Results. We report the outcome of 26 pregnant women exposed to gadolinium derivatives in the first trimester without adverse effect on pregnancy and neonatal outcome. Conclusions. Currently, this study represents the only prospective investigation of gadolinium derivatives in pregnancy, but more data are necessary to exclude a teratogenic risk.